WHO Unveils New TB Injection Targets to Streamline Treatment
The WHO aims to simplify tuberculosis treatment with new injection protocols, potentially transforming care for millions.
New targets propose a single injection for TB prevention and fewer treatment visits.
India accounts for 25% of global TB cases, highlighting the need for improved treatment options.
Proposed injectables must prove safety and effectiveness before approval.
The World Health Organization (WHO) has announced new global targets aimed at revolutionizing tuberculosis (TB) treatment through long-acting injectable medicines. These targets, released on October 28, 2026, suggest that future preventive measures could rely on a single-dose injection, while treatment for active TB should ideally be completed within four months, requiring no more than three visits for dosing.
Historically, TB has posed a significant public health challenge, particularly in India, which represents about 25% of the world's TB cases, as noted in the WHO’s Global Tuberculosis Report 2025. In 2024, approximately 10.7 million individuals were diagnosed with TB globally, and the disease claimed 1.23 million lives. The lengthy treatment regimens, often stretching over several months, coupled with side effects and logistical challenges, have made adherence to medication a persistent issue.
The newly proposed long-acting injectables are designed to gradually release medication, ensuring therapeutic levels are sustained over extended periods. The WHO emphasizes that these treatments must demonstrate safety and effectiveness comparable to existing oral medications to be viable alternatives. This innovation could alleviate the burden on patients, particularly in remote and economically disadvantaged areas of India, by reducing the frequency of hospital visits and associated costs.
The implications of these targets are profound, especially for India, where the healthcare system faces challenges in accessibility and affordability. The introduction of these injectables could significantly ease the financial strain on patients and improve treatment adherence, thereby potentially reducing the incidence of drug-resistant TB.
However, it is important to note that these targets are focused on drug development and do not represent approved treatments. The candidate medicines will need to undergo rigorous clinical trials and regulatory evaluations before they can be made available to the public. Until then, existing TB treatment protocols will remain unchanged, highlighting the need for continued vigilance in managing this global health crisis.
